TALARIS THERAPEUTICS
Talaris Therapeutics is a operator of a biotechnology company engaged in the development of innovative cellular therapies. The company's proprietary allogeneic cell therapy product has shown to induce tolerance in recipients of solid organ transplants from unmatched and unrelated donors, enabling living donor kidney transplant recipients to wean completely off immunosuppression one year after transplant.
TALARIS THERAPEUTICS
Industry:
Biotechnology Health Care Therapeutics
Founded:
2002-01-01
Address:
Wellesley, Massachusetts, United States
Country:
United States
Website Url:
http://www.talaristx.com
Total Employee:
11+
Status:
Active
Email Addresses:
[email protected]
Total Funding:
215 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default Google Font API Google Analytics Apple Mobile Web Clips Icon WordPress Google Universal Analytics Font Awesome
Similar Organizations
Acrivon Therapeutics
Acrivon Therapeutics is a precision oncology therapeutics company specializing in drug development through early clinical treatment success.
Innovative Cellular Therapeutics
Innovative Cellular Therapeutics is a Shanghai-based biotechnology company engaged in research and development of cell therapy.
Current Advisors List
Current Employees Featured
Founder
Stock Details
Investors List
Viking Global Investors
Viking Global Investors investment in Series B - Talaris Therapeutics
Eventide
Eventide investment in Series B - Talaris Therapeutics
Longitude Capital
Longitude Capital investment in Series B - Talaris Therapeutics
Surveyor Capital
Surveyor Capital investment in Series B - Talaris Therapeutics
Pamoja Capital
Pamoja Capital investment in Series B - Talaris Therapeutics
Invus
Invus investment in Series B - Talaris Therapeutics
Aisling Capital
Aisling Capital investment in Series B - Talaris Therapeutics
BlackRock
BlackRock investment in Series B - Talaris Therapeutics
Blackstone Life Sciences
Blackstone Life Sciences investment in Series B - Talaris Therapeutics
Logos Capital
Logos Capital investment in Series B - Talaris Therapeutics
Key Employee Changes
Date | New article |
---|---|
2021-03-04 | Talaris Therapeutics Appoints Mary Kay Fenton as Chief Financial Officer |
Official Site Inspections
http://www.talaristx.com Semrush global rank: 3.33 M Semrush visits lastest month: 4.81 K
- Host name: 104.21.54.28
- IP address: 104.21.54.28
- Location: United States
- Latitude: 37.751
- Longitude: -97.822
- Timezone: America/Chicago